2435

Short Inhibitory Peptide for Treatment of Medical Conditions

Naor David, HUJI, School of Medicine - IMRIC, Immunology and Cancer Research

 

Categories

Peptide/Protein, Inflammation, Autoimmunity, Rheumatoid arthritis

Development Stage

Feasibility demonstrated in mouse models. Proven Long term stability

Patent Status

Provisional Patent application was submitted

Market

Prevalence of rheumatoid arthritis is relatively constant in many populations at between 0.5 and 1%. Annual revenues from the main prescription anti-inflammatory drugs worldwide, including non steroidal anti-inflammatory drugs  (NSAIDs), anti-rheumatic corticosteroid combinations and specific anti-rheumatics expected to reach $27 billion worldwide by 2015

Our Innovation

  • Short 5 amino acid peptide, that includes the functional pathological domain of human rheumatoid  arthritis (RA)-specific protein,  displays substantial anti-arthritic activity in a two different mouse models of RA (collagen induced arthritis), even when injected after the disease onset (Fig 1). Efficacy of 5AA (Amino Acid)  RA peptide was proved in 7 different experiences and injection protocol was established.
  • While the peptide reduces arthritic activity in the mouse model, it does not influence the immune response in general. For example, delayed type hypersensitivity reaction is not affected by the peptide and there is no generation of anti-peptide antibodies.
  • The peptide is found to be stable for 22 weeks at room temperature lyophilized state as well as in solution.

Highlights

  • Short peptide that includes the functional domain of the RA-specific protein and may display disease-blocking activity
  • Current RA drugs are non-specific, generate complications in some patients and affect only 75% of patients.
  • The pathological protein domain that includes our peptide sequence was detected in synovial fluid cells (SFC) of 33 out of 41 RA patients (75%) and in 7 out of 7 psoriatic arthritis patients (100%) but wasn't detected in peripheral blood leukocytes (PBL) of the same patients, implying on high specificity.  Flow cytometry reveals that a specific antibody detects the pathological RA protein (which includes the 5aa peptide) in the synovial fluid inflammatory cells of   an RA patient ,but not of the peripheral blood cells (PBLs) of the same patient

 Key Features

  • Due to the fact that the  5 AA RA peptide is short in size it may have the potential to be converted into tablets and ointment for oral and topical treatment of RA
  • Development and production cost of 5 AA peptides is relatively low and is likely to be easily scalable
  • Peptide designed to maintain disease-specific - therapeutic activity seems to be not accompanied by complications and side effects

Additional indications

  • May also applicable for psoriatic arthritis (PsA) which affects 4 million people

 

3_0.jpg

Patent Status

Published US 2017 /0218045A1; 2017-525387

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608
Contact ME:
Image CAPTCHA